NEW YORK (GenomeWeb News) – The US Food and Drug Administration has notified CombiMatrix that its microarray-based diagnostic service for identifying genetic disorders does not fall under its recent guidance covering in vitro diagnostic multivariate index assays, and therefore will not be subject to some new regulations.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Hundreds of scientists have signed a letter criticizing the open-access Plan S, ScienceInsider reports.

NPR speaks with Rep. Eddie Bernice Johnson (D-Texas) about the US House of Representatives science committee.

A start-up company aiming to match cancer patients to treatments closes after about six weeks, Stat News reports.

In PLOS this week: somatic mutation associations unearthed in thousands of cancer exomes, pathogen detection assay, and more.